SCHEMBL5656506

SCHEMBL5656506

Cn1ncc2cc(CC(N)C(=O)N3CCN(C4CCNCC4)CC3)ccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 4/20 0.41
CCNC P24863 5/20 0.40
CDK8 P49336 5/20 0.40
OPRD1 P41143 1/20 0.40
ROCK2 O75116 2/20 0.39
CYP3A4 P08684 2/20 0.39
CREBBP Q92793 1/20 0.38
DPP4 P27487 1/20 0.38
CTSC P53634 1/20 0.37
KDM2B Q8NHM5 1/20 0.36
MPO P05164 1/20 0.36
HTR2A P28223 1/20 0.36
PASK Q96RG2 1/20 0.36
CDK19 Q9BWU1 1/20 0.36
AKT1 P31749 1/20 0.36
DRD4 P21917 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
PLA2G7 Q13093 1/20 0.35
MGLL Q99685 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5658864 0.93 KDM1A (0.43) KDM1ACCNCCDK8OPRD1ROCK2
SCHEMBL5661343 0.91 KDM1A (0.41) KDM1ACCNCCDK8OPRD1ROCK2
SCHEMBL5658735 0.89 CCNC (0.45) KDM1ACCNCCDK8OPRD1ROCK2
SCHEMBL5662346 0.89 KDM1A (0.44) KDM1ACCNCCDK8OPRD1ROCK2
SCHEMBL5661149 0.84 CALCA (0.37) ROCK2CYP3A4
SCHEMBL5658225 0.82 OPRD1 (0.44) KDM1ACCNCCDK8OPRD1ROCK2
SCHEMBL5658567 0.81 CYP3A4 (0.58) ROCK2CYP3A4AKT1
SCHEMBL3277831 0.79 OPRD1 (0.41) OPRD1ROCK2CYP3A4DPP4AKT1
SCHEMBL5660890 0.79 CYP3A4 (0.46) OPRD1ROCK2CYP3A4DPP4AKT1
SCHEMBL5660905 0.78 CYP3A4 (0.55) ROCK2CYP3A4AKT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US claimed
US-7205294-B2 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-04-17 US disclosed
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2005-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050227968-A1 Selected CGRP-antagonists process for preparing them and their use as pharmaceutical compositions BDKRB1, BDKRB2, CALCRL KDM1A 4125/4885CCNC 2475/4885CDK8 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.